Trioxia

Trioxia is a biotechnology company focused on transforming cancer treatment through the development of advanced targeted alpha therapies (TAT). The company employs a proprietary pre-targeting platform that utilizes bioorthogonal click chemistry to deliver potent alpha-emitting isotopes, such as Actinium-225, directly to tumor sites. This approach separates the targeting phase from the radioactive delivery phase, significantly reducing systemic radiation exposure and improving the therapeutic index compared to conventional radiopharmaceuticals. Trioxia's technology is designed to be modular, allowing for the treatment of various solid tumors by pairing different targeting vectors with their specialized radiolabeled payloads.